Bioventus (BVS) Assets (2020 - 2026)

Bioventus has reported Assets for 7 years, with the latest figure at $650.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 5.91% year-over-year to $650.5 million; the trailing twelve-month figure through Mar 2026 stood at $650.5 million (down 5.91% YoY), and the FY2025 full-year result was $683.6 million, down 6.1% from the prior year.
• Assets for Q1 2026 stood at $650.5 million, down from $683.6 million in the prior quarter.
• The five-year high for Assets was $1.4 billion in Q4 2022, with the low at $650.5 million in Q1 2026.
• Historically, Assets has averaged $884.7 million across 5 years, with a median of $794.2 million in 2024.
• Annual changes were most pronounced in 2022 — Assets jumped 113.51% — and 2023, when it tumbled 41.98%.
• Bioventus' Assets stood at $1.4 billion in 2022, then plunged by 40.92% to $810.9 million in 2023, then fell by 10.23% to $728.0 million in 2024, then dropped by 6.1% to $683.6 million in 2025, then declined by 4.83% to $650.5 million in 2026.
• The last three Assets figures came in at $650.5 million (Q1 2026), $683.6 million (Q4 2025), and $701.6 million (Q3 2025), per Business Quant data.